WebFeb 27, 2024 · FDA approved Claros® point-of-care (POC) PSA test: On February 1, 2024, OPKO announced that the FDA approved the Company’s point-of-care Sangia Total PSA Test using the Claros 1 Analyzer. The Company is taking steps to obtain CLIA waiver for the test and analyzer, which would permit the test to be performed by most medical … WebOur History. Claros Analytics was founded by healthcare consulting actuaries looking for a better way to price risk in the industry. The existing rating manuals weren’t producing …
OPKO Health Submits Premarket Approval Application with FDA …
WebThe Claros 1 Analyzer is a novel diagnostic instrument system that can provide rapid, quantitative test results in 10 minutes – right in the physician’s office. The Claros 1 … WebJan 13, 2015 · The goal of the grant is to develop a rapid diagnostic test based upon novel antigens that increase the specificity and sensitivity of the current laboratory assays and … Announcements - OPKO Claros1 Analyzer Selected for Development of a Rapid … Pipelines using the same proprietary platforms, such as the long acting CTP, … Our Products - OPKO Claros1 Analyzer Selected for Development of a Rapid … Company Contact OPKO Health, Inc. 4400 Biscayne Boulevard Miami, FL 33137 T: … Events - OPKO Claros1 Analyzer Selected for Development of a Rapid Lyme … Financial Information - OPKO Claros1 Analyzer Selected for Development of a … MOD-13012 (CTP-IGF-1) Severe primary insulin-like growth factor 1 (IGF-1) … Claros® 1. The Claros ® 1 device is a point-of-care, bench top diagnostic instrument … Contact - OPKO Claros1 Analyzer Selected for Development of a Rapid Lyme … Locations - OPKO Claros1 Analyzer Selected for Development of a Rapid … sara chase phd
OPKO Health (OPK) Reports FDA Approval for Point-of-Care …
WebFeb 1, 2024 · MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has … WebApr 17, 2024 · This test is used in combination with the Claros 1 Analyzer ( Figure 1). 11 The blood sample is collected from a finger stick with the Sample Collector. WebFeb 1, 2024 · Opko Health Inc.'s point-of-care Sangia Total Prostate Specific Antigen, test was approved by the U.S. Food and Drug Administration for the detection of prostate cancer in men aged 50 years and older. The Miami-based diagnostics and pharmaceuticals company said the Sangia PSA test will be used with the Claros 1 Analyzer. The product … sara chasteen